Additional ADCs that are currently being studied in early-phase trials for metastatic TNBC include ladiratuzumab-vedotin (humanized IgG1 antibody directed against LIV-1) with pembrolizumab (NCT03310957), U3-1302 (humanized anti-HER3 antibody linked with a topoisomerase I inhibitor, NCT04699630), CAB-ROR2-ADC (conditionally active biologic ROR2-targted ADC, NCT03504488), and anti-CA6-DM4 immunoconjugate (humanized DS6 antibody directed against tumor-associated sialoglycotope CA6 conjugated to maytansinoid DM4, NCT02984683). Here, ROR2 is linked to neoplasm.